ASTRAZENECA PLC — 6-K Filings
1,550 6-K filings on record
This page lists all 6-K filings submitted to the SEC by ASTRAZENECA PLC (AZN), sorted by most recent first. Each row links to the full filing on EdgarLookup. ASTRAZENECA PLC has filed 1,550 6-K documents with the SEC since 2018. To view all SEC filings by ASTRAZENECA PLC, see the full filings list.
All
11-K
144
20-F
20-F/A
25
25-NSE
3
3/A
4
424B2
424B3
424B5
425
6-K
6-K/A
8-A12B
8-A12B/A
CERT
CERTNYS
CORRESP
CT ORDER
DFAN14A
EFFECT
F-3
F-3ASR
F-4
F-4/A
F-6
F-6 POS
F-6EF
FWP
IRANNOTICE
NO ACT
S-1
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13D/A
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-003772 | Apr 1, 2025 | — |
| 6-K | IMFINZI APPROVED IN THE US FOR BLADDER CANCER | 0001654954-25-003589 | Mar 31, 2025 | — |
| 6-K | CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL | 0001654954-25-003590 | Mar 31, 2025 | — |
| 6-K | AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING | 0001654954-25-003128 | Mar 21, 2025 | — |
| 6-K | ASTRAZENECA TO ACQUIRE ESOBIOTEC | 0001654954-25-002837 | Mar 17, 2025 | — |
| 6-K | IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC | 0001654954-25-002839 | Mar 17, 2025 | — |
| 6-K | ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT | 0001654954-25-002841 | Mar 17, 2025 | — |
| 6-K | HOLDING(S) IN COMPANY | 0001654954-25-002669 | Mar 12, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-002424 | Mar 7, 2025 | — |
| 6-K | FORM 6-K | 0001104659-25-021517 | Mar 7, 2025 | — |
| 6-K | NOTICE OF AGM | 0001654954-25-002413 | Mar 7, 2025 | — |
| 6-K | IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER | 0001654954-25-002412 | Mar 7, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-002350 | Mar 6, 2025 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-002308 | Mar 5, 2025 | — |
| 6-K | IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN | 0001654954-25-002166 | Mar 3, 2025 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-002199 | Mar 3, 2025 | — |
| 6-K | ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER | 0001654954-25-002102 | Feb 28, 2025 | — |
| 6-K | CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER | 0001654954-25-001920 | Feb 26, 2025 | — |
| 6-K | FILING OF FORM 20-F WITH SEC | 0001654954-25-001661 | Feb 19, 2025 | — |
| 6-K | HOLDING(S) IN COMPANY | 0001654954-25-001625 | Feb 18, 2025 | — |
| 6-K | DIRECTORATE CHANGE | 0001654954-25-001614 | Feb 18, 2025 | — |
| 6-K | FORM 6-K | 0001104659-25-014732 | Feb 18, 2025 | — |
| 6-K | ANNUAL FINANCIAL REPORT | 0001654954-25-001619 | Feb 18, 2025 | — |
| 6-K | FINAL RESULTS | 0001654954-25-001189 | Feb 6, 2025 | — |
| 6-K | IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC | 0001654954-25-001005 | Feb 3, 2025 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-001087 | Feb 3, 2025 | — |
| 6-K | ENHERTU APPROVED IN US FOR BREAST CANCER POST ET | 0001654954-25-000846 | Jan 28, 2025 | — |
| 6-K | DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER | 0001654954-25-000565 | Jan 21, 2025 | — |
| 6-K | CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL | 0001654954-25-000518 | Jan 17, 2025 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-25-000031 | Jan 2, 2025 | — |
| 6-K | DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU | 0001654954-24-015891 | Dec 26, 2024 | — |
| 6-K | TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL | 0001654954-24-015839 | Dec 23, 2024 | — |
| 6-K | DIRECTORATE CHANGE | 0001654954-24-015567 | Dec 16, 2024 | — |
| 6-K | IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC | 0001654954-24-015165 | Dec 5, 2024 | — |
| 6-K | ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL | 0001654954-24-015151 | Dec 4, 2024 | — |
| 6-K | BLOCK LISTING INTERIM REVIEW | 0001654954-24-015049 | Dec 2, 2024 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-24-015048 | Dec 2, 2024 | — |
| 6-K | TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER | 0001654954-24-014843 | Nov 25, 2024 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-014697 | Nov 20, 2024 | — |
| 6-K | TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA | 0001654954-24-014570 | Nov 18, 2024 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-014508 | Nov 15, 2024 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-014517 | Nov 15, 2024 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-014235 | Nov 13, 2024 | — |
| 6-K | DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN | 0001654954-24-014084 | Nov 12, 2024 | — |
| 6-K | 9M AND Q3 2024 RESULTS | 0001654954-24-014089 | Nov 12, 2024 | — |
| 6-K | KOMET PHASE III TRIAL MET PRIMARY ENDPOINT | 0001654954-24-014093 | Nov 12, 2024 | — |
| 6-K | ASTRAZENECA INVESTS $3.5 BILLION IN US | 0001654954-24-014095 | Nov 12, 2024 | — |
| 6-K | TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS | 0001654954-24-013972 | Nov 8, 2024 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-24-013617 | Nov 1, 2024 | — |
| 6-K | AZN CHINA PRESIDENT UNDER INVESTIGATION | 0001654954-24-013471 | Oct 30, 2024 | — |